Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov;396(11):3221-3232.
doi: 10.1007/s00210-023-02533-2. Epub 2023 May 20.

In vitro evaluation of anticoagulant therapy management when urgent percutaneous coronary intervention is required in rivaroxaban-treated patients

Mehmet Melek  1 , Hasan Ari  2 , Selma Ari  1 , Mehmet Can Cilgin  1 , Mücahit Yarar  1 , Kagan Huysal  3 , Fahriye Vatansever Ağca  1 , Tahsin Bozat  1
Affiliations

In vitro evaluation of anticoagulant therapy management when urgent percutaneous coronary intervention is required in rivaroxaban-treated patients

Mehmet Melek et al. Naunyn Schmiedebergs Arch Pharmacol. 2023 Nov.

Abstract

We investigated in vitro the management of intraprocedural anticoagulation in patients requiring immediate percutaneous coronary intervention (PCI) while using regular direct oral anticoagulants (DOACs). Twenty-five patients taking 20 mg of rivaroxaban once daily comprised the study group, while five healthy volunteers included the control group. In the study group, a beginning (24 h after the last rivaroxaban dose) examination was performed. Then, the effects of basal and four different anticoagulant doses (50 IU/kg unfractionated heparin (UFH), 100 IU/kg UFH, 0.5 mg/kg enoxaparin, and 1 mg/kg enoxaparin) on coagulation parameters were investigated at the 4th and 12th h following rivaroxaban intake. The effects of four different anticoagulant doses were evaluated in the control group. The anticoagulant activity was assessed mainly by anti-factor Xa (anti-Xa) levels. Beginning anti-Xa levels were significantly higher in the study group than in the control group (0.69 ± 0.77 IU/mL vs. 0.20 ± 0.14 IU/mL; p < 0.05). The study group's 4th and 12th-h anti-Xa levels were significantly higher than the beginning level (1.96 ± 1.35 IU/mL vs. 0.69 ± 0.77 IU/mL; p < 0.001 and 0.94 ± 1.21 IU/mL vs. 0.69 ± 0.77 IU/mL; p < 0.05, respectively). Anti-Xa levels increased significantly in the study group with the addition of UFH and enoxaparin doses at the 4th and 12th h than the beginning (p < 0.001 at all doses). The safest anti-Xa level (from 0.94 ± 1.21 to 2.00 ± 1.02 IU/mL) was achieved 12 h after rivaroxaban with 0.5 mg/kg enoxaparin. Anticoagulant activity was sufficient for urgent PCI at the 4th h after rivaroxaban treatment, and additional anticoagulant administration may not be required at this time. Twelve hours after taking rivaroxaban, administering 0.5 mg/kg of enoxaparin may provide adequate and safe anticoagulant activity for immediate PCI. This experimental study result should confirm with clinical trials (NCT05541757).

Keywords: Enoxaparin; Percutaneous coronary intervention; Rivaroxaban; Unfractionated heparin.

PubMed Disclaimer

References

    1. Asmis LM, Alberio L, Angelillo-Scherrer A, Korte W, Mendez A, Reber G et al (2012) Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories. Thromb Res 129:492–498. https://doi.org/10.1016/j.thromres.2011.06.031 - DOI - PubMed
    1. Batra G, Svennblad B, Held C, Jernberg T, Johanson P, Wallentin L et al (2016) All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcome. Heart 102:926–933. https://doi.org/10.1136/heartjnl-2015-308678 - DOI - PubMed
    1. Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA (1994) Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 271:840–844 - DOI - PubMed
    1. Beyer J, Trujillo T, Fisher S, Ko A, Lind SE, Kiser TH (2016) Evaluation of a heparin-calibrated antifactor Xa assay for measuring the anticoagulant effect of oral direct Xa inhibitors. Clin Appl Thromb Hemost 22:423–428. https://doi.org/10.1177/1076029616629759 - DOI - PubMed
    1. Braga CG, Ramos V, Martins J, Arantes C, Abreu G, Vieira C et al (2015) Impact of atrial fibrillation type during acute coronary syndromes: clinical features and prognosis. Rev Port Cardiol 34:403–410. https://doi.org/10.1016/j.repc.2015.01.010 - DOI - PubMed

Associated data

LinkOut - more resources